Výsledky vyhledávání - "Ivan Marchena"

Akademický článek

1203 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE

Autor: ANDRAS PERL, Hajra Tily, Zhi-wei Lai, Julie Yu, Stephen V Faraone, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Maha Dawood, Ricardo Garcia, Lisa Francis, Paul E Phillips

Publikováno v: Lupus Science and Medicine, Vol 9, Iss Suppl 3 (2022)

Externí odkaz: https://doaj.org/article/0cef401f7fc543deb878c26431ce792f

Zobrazit plný text záznamu

Autor: Zhi-Wei Lai, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Julie Yu, Maha Dawood, Ricardo Garcia, Hajra Tily, Lisa Francis, Stephen V Faraone, Paul E Phillips, Andras Perl

Publikováno v: 2022 Lupus 21st Century Encore.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::104b075ad0e17b805ae16190c8329a0e
https://doi.org/10.1136/lupus-2022-lupus21century.85

Zobrazit plný text záznamu

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Autor: Paul E. Phillips, Andras Perl, Ricardo Garcia, Zhi-Wei Lai, Ryan Kelly, Ashwini Shadakshari, Lisa Francis, Julie Yu, Ivan Marchena, Hajra Tily, Stephen V. Faraone, Maha Dawood, Thomas Winans

Publikováno v: The Lancet. 391:1186-1196

Summary Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been develop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36dd7eaa4eec9cb373fa833436e7ee05
https://doi.org/10.1016/s0140-6736(18)30485-9

Zobrazit plný text záznamu

BD-02 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE

Autor: Paul E. Phillips, Ryan Kelly, Zhi-Wei Lai, Lisa Francis, Andras Perl, Maha Dawood, Julie Yu, Ricardo Garcia, Thomas Winans, Stephen V. Faraone, Ashwini Shadakshari, Hajra Tily, Ivan Marchena

Publikováno v: Big Data Analyses.

Background Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction that has been attributed to mechanistic target of rapamycin activation. Therefore, safety, tolerance, and efficacy of rapamycin were examined in a prospective biomarker

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f4eacfbd35b9bb7f18740bf79b16c3e
https://doi.org/10.1136/lupus-2018-lsm.26

Zobrazit plný text záznamu

Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus

Autor: Jianghong Yu, Andras Perl, Lisa Francis, Phillip Aleksiejuk, Zachary Oaks, Steve K. Landas, Katalin Banki, Jessica Patel, Ivan Marchena-Mendez, Yuxin Liu, Eduardo Bonilla

Liver disease (LD), defined as ≥ 2-fold elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT), was examined in a longitudinal study of systemic lupus erythematosus (SLE) patients. Among 435 patients, 90 (20.7%) had LD with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7919e542737485cbec3cc53c1e47695b
https://europepmc.org/articles/PMC4583603/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání